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rophylactic Pre-Operative
oronary Revascularization
s the Phoenix Awakening?*
iora Landesberg, MD, DSC,†
orris Mosseri, MD‡
erusalem and Kfar-Saba, Israel
xactly 30 years ago, Hertzer et al. (1) published the first in a
eries of reports on thousands of patients who underwent
outine coronary angiography before major vascular surgery.
heir landmark studies were the basis for our current recog-
ition that vascular surgery patients have a high prevalence of
ignificant coronary artery disease (CAD): 60% have 1 or more
oronary arteries with 70% stenosis, 18% have severe triple-
essel disease, and 4% have left main disease (2). Subsequently,
ertzer et al. (1) showed that selective pre-operative coronary
rtery bypass graft surgery (CABG) in patients with severe
AD lowered the perioperative and long-term mortality rel-
tive to patients with similar degrees of CAD not treated with
ABG. Numerous subsequent studies confirmed that major
ascular surgery is associated with a high risk for both periop-
rative and long-term cardiac morbidity and mortality. Many
See page 989
ther studies demonstrated that this risk is predicted by
schemia on pre-operative noninvasive cardiac testing (radio-
uclide imaging or dobutamine stress echocardiography).
owever, the data that pre-operative coronary revasculariza-
ion (PCR), mainly by CABG, improves perioperative or
ong-term outcome after major vascular surgery came from
etrospective observational studies only (3). Moreover, since
CR is not free of complications, serious questions were raised
s to the overall risk-benefit ratio of PCR before major vascular
urgery, questions that could only be answered by large-scale
andomized controlled trials (RCTs).
Lately, 2 RCTs—the CARP (Coronary Artery Revasculariza-
ion Prophylaxis) trial (4) and the DECREASE (Dutch Echo-
ardiographic Cardiac Risk Evaluation Applying Stress Echo
tudy Group)-V (5) study—examined the role of PCR before
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the author and do not necessarily represent the view of JACC or the American
ollege of Cardiology.
From the †Cardiothoracic and Vascular Anesthesia Division, Hebrew University,f
adassah Medical Center, Jerusalem, Israel; and the ‡Cardiology Division, Meir
edical Center, Kfar-Saba, Israel.ajor vascular surgery. Both trials found absolutely no perioper-
tive or long-term benefit to PCR over medical therapy before
ascular surgery. Unfortunately however, even these RCTs were
ot free of serious limitations. The CARP trial screened 5,859
ascular surgery patients from 18 Veterans Administration hospi-
als in the U.S., yet without a unified method of screening in all
nstitutions. Subsequently, only a small proportion (8.9%) of
creened patients was randomized. Only 44% of randomized
atients had moderate-large ischemia on pre-operative nuclear
maging, and only 32% had triple-vessel disease (2.9% of all
creened patients), indicating a potential selection bias with the
ossibility that mainly patients less likely to benefit from PCR
ere included in the trial. Patients with left-main CAD were
xcluded by design from randomization. Moreover, on reanalysis
f the CARP study data, patients who had complete coronary
evascularization with CABG had fewer post-operative cardiac
omplications (6), and among patients who were not included in
he randomization, those with left main disease had better survival
f treated with PCR (7). In contrast, the DECREASE-V trial
imed to randomize patients with the most severe CAD. How-
ver, this relatively small trial (n  101) eventually randomized
atients who were too ill for PCR and surgery. In the revascular-
zation arm, 100% had history of myocardial infarction, 51% had
ngoing angina, 47% had congestive heart failure, 37% had
iabetes mellitus, 41% had a history of cerebrovascular accident,
nd 18% had renal failure, in addition to extensive ischemia on
oninvasive pre-operative testing. Moreover, apparently all 49
atients randomly assigned to the revascularization arm were
ompelled to undergo PCR, although most studies show that up
o one-third of vascular surgery patients with severe ischemia on
oninvasive testing cannot undergo coronary revascularization
ecause of unsuitable coronary anatomy, poor runoff, multiple
mall-vessel disease, or chronic total obstructions not amenable to
ercutaneous coronary intervention, or because they are too sick
or CABG. Subsequently, the DECREASE-V trial patients
uffered exceptionally high perioperative (11% to 22%) and 1-year
ortality regardless of PCR. The authors of this editorial have
reviously shown that major vascular surgery patients with numer-
us risk factors have a poor post-operative prognosis irrespective of
CR (8). Therefore, major vascular surgery patients deserve
areful pre-operative clinical assessment and judgment as to who
ay or may not benefit from coronary intervention and strict,
linded randomization can do harm to such patients.
Despite the above limitations, the impact of the CARP and
ECEASE-V trials on clinical practice and published guidelines
orldwide was enormous. Coronary revascularization is subse-
uently rarely recommended before major vascular surgery, and
ven the demand for noninvasive pre-operative cardiac testing in
ajor vascular patients has decreased substantially. It is against this
ackground that the study by Monaco et al. (9) in this issue of the
ournal has surprisingly emerged.
Monaco et al. (9) elegantly showed in a RCT that a strategy
f routine pre-operative coronary angiography and subsequent
elective PCR provides better long-term survival and event-
ree survival for patients undergoing abdominal aortic surgery,
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Pre-Operative Coronary Revascularization September 8, 2009:997–8ompared with a strategy of selective coronary angiography and
CR, performed only after pre-operative noninvasive testing
howing significant ischemia. There was also a tendency to
mproved perioperative outcome (although not statistically
ignificant). Included in the randomization were all patients
ith 2 RCRI criteria. Patients in the routine angiography
rm underwent more PCRs (58.1% vs. 40.1%; p  0.01).
nterestingly, the beneficial effect of PCR in the routine
ngiography arm was on top of strong beta-blockade with the
onselective beta-blocker carvedilol, titrated to quite high
oses to reach the effect of resting pre-operative heart rate of
60 beats/min. There are 2 main findings in this trial: 1) PCR
mproves outcome for this subset of medium-high risk vascular
urgery patients; and 2) routine pre-operative coronary angiog-
aphy provides better screening of vascular surgery patients
han does noninvasive testing.
How can we reconcile the sharp conflict between the
ositive results of the trial by Monaco et al. (9) and the negative
esults of the previous 2 RCTs? First, unlike the previous
CTs, this trial included only patients undergoing abdom-
nal aortic surgery and not lower extremity bypass opera-
ions. The latter are less stressful operations, associated with
ower perioperative morbidity and mortality. Clearly, the
ECREASE-V patients were much sicker, with more cardiac
nd noncardiac comorbidities than the patients in the present
tudy with poorer prognosis regardless of any pre-operative
reatment. Conversely, the patients in the present trial had
ore extensive CAD, including left main disease and a higher
revalence of triple-vessel disease than the CARP trial pa-
ients. Importantly, patients in the systematic pre-operative
oronary angiography group underwent more PCRs with
ff-pump CABG than PCI compared with the control group
47.5% vs. 28.6%, respectively, with a tendency for statistical
ignificance: p 0.08). It is possible, therefore, that more patients
ith left main disease and triple-vessel disease underwent off-
ump CABG than PCI, and these results translated into a
ignificantly better long-term outcome in the systematic coronary
ngiography group who underwent more CABG than PCI, in
orroboration with previous studies that found better outcome
ith CABG than PCI in similar patients (6,10).
Will this new RCT lead to a change in practice back to
ore pre-operative coronary revascularizations or to routine
oronary angiography as Hertzer advocated 30 years ago? Time
ill tell. The study by Monaco et al. (9) suggests that routine
re-operative coronary angiography is better than noninvasive
ardiac testing for detecting patients who may benefit from
uccessful PCR. This relatively small trial must be corroborated
y additional, preferably larger studies. The possibility of
creening patients by computed tomography or magnetic
esonance coronary angiography, rather than routine coronary
ngiography, should also be explored. The current practice of
ndovascular abdominal aneurysm repair, which is less stressful
nd associated with fewer perioperative complications, dimin-
shes, although does not eliminate, the need for open aortic
epairs, pre-operative cardiac evaluations, and eventual PCR.
K
aevertheless, it is safe to say, on the basis of currently
ccumulated data, that vascular surgery patients, particularly
hose with extensive and complex CAD and a high SYNTAX
Synergy between PCI with TAXUS and Cardiac Surgery)
core (11), fare better in the long run with CABG than with
CI (6,10). Moreover, the current guidelines demanding
rolonged dual-antiplatelet therapy, even after successful cor-
nary stent implantation (at least 4 weeks for bare-metal stent
nd up to 1 year after drug-eluting stent implantation), limit
he ability to use PCI as the method for coronary revascular-
zation before major surgery. Above all, risk stratification of
atients who are candidates for vascular surgery is frequently
uzzling, and the treating physicians must rely on their best
edical judgment whether to pursue pre-operative noninvasive
r invasive testing as well as coronary revascularization proce-
ures with these high-risk patients.
eprint requests and correspondence: Dr. Giora Landesberg,
ebrew University, Hadassah Medical Center, Department of
nesthesiology and CCM, Kyriat-Hadassah, Ein Kerem, Jerusa-
em 91120, Israel. E-mail: gio@cc.huji.ac.il.
EFERENCES
1. Hertzer NR, Young JR, Kramer JR, et al. Routine coronary angiog-
raphy prior to elective aortic reconstruction: results of selective myo-
cardial revascularization in patients with peripheral vascular disease.
Arch Surg 1979;114:1336–44.
2. Hertzer NR, Bever EG, Young JR, et al. Coronary artery disease in
peripheral vascular patients: a classification of 1000 coronary angiograms
and results of surgical management. Ann Surg 1984;199:223–33.
3. Kertai MD. Preoperative coronary revascularization in high-risk pa-
tients undergoing vascular surgery: a core review. Anesth Analg
2008;106:751–8.
4. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascu-
larization before elective major vascular surgery. N Engl J Med
2004;351:2795–804.
5. Poldermans D, Schouten O, Vidakovic R, et al., for the DECREASE
Study Group. A clinical randomized trial to evaluate the safety of a
noninvasive approach in high-risk patients undergoing major vascular
surgery. J Am Coll Cardiol 2007;49:1763–9.
6. Ward HB, Kelly RF, Thottapurathu L, et al. Coronary artery bypass
grafting is superior to percutaneous coronary intervention in preven-
tion of perioperative myocardial infarctions during subsequent vascular
surgery. Ann Thorac Surg 2006;82:795–801.
7. Garcia S, Moritz TE, Ward HB, et al. Usefulness of revascularization
of patients with multivessel coronary artery disease before elective
vascular surgery for abdominal aortic and peripheral occlusive disease.
Am J Cardiol 2008;102:809–13.
8. Landesberg G, Berlatzky Y, Bocher M, et al. A clinical survival score
predicts the likelihood to benefit from preoperative thallium scanning
and coronary revascularization before major vascular surgery. Eur
Heart J 2006;28:533–9.
9. Monaco M, Stassano P, Di Tomasso L, et al. Systematic strategy of
prophylactic coronary angiography improves long-term outcome after
major vascular surgery in medium- to high-risk patients: a prospective,
randomized study. J Am Coll Cardiol 2009;54:989–96.
0. Landesberg G, Mosseri M, Wolf YG, et al. Preoperative thallium
scanning, selective coronary revascularization, and long-term survival
after major vascular surgery. Circulation 2003;108:177–83.
1. Lange RA, Hillis LD. Coronary revascularization in context. N Engl
J Med 2009;360:1024–6.ey Words: vascular surgery y risk stratification y coronary
ngiography y peripheral vascular disease y revascularization.
